Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

159.25 

1.00 0.6%

as of Aug 19 '19

52 Week Range:

114.27 197.00


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 20.16
24.50
26.09
27.42
30.02
21.49
109.59
183.89
253.20
200.57
211.99
growth rate 21.5% 6.5% 5.1% 9.5% -28.4% 410.0% 67.8% 37.7% -20.8% 5.7%
Earnings BIT 787.20
848.50
170.80
1,300.00
1,530.00
1,730.00
-659.50
34.70
-365.20
65.20
384.50
growth rate 7.8% -79.9% 661.1% 17.7% 13.1% -100.0% 100.0% -100.0% 100.0% 489.7%
Avg.PE 21.32
31.06
5,000.00
29.15
25.64
26.46
46.64
27.89
6.43
5.24
24.47
growth rate 45.7% 15,997.9% -99.4% -12.0% 3.2% 76.3% -40.2% -77.0% -18.5% 367.0%
ROA 6.67
4.59
3.12
4.17
0.94
-4.08
-4.33
3.91
11.10
-3.56
-4.67
growth rate -31.2% -32.0% 33.7% -77.5% -100.0% 0.0% 100.0% 183.9% -100.0% 0.0%
ROE 12.05
8.65
5.85
7.62
2.63
-11.23
-8.61
7.37
20.56
-6.28
-7.68
growth rate -28.2% -32.4% 30.3% -65.5% -100.0% 0.0% 100.0% 179.0% -100.0% 0.0%
ROIC 8.75
6.42
5.78
6.89
1.93
-3.28
-3.99
5.62
13.83
-3.98
-4.79
growth rate -26.6% -10.0% 19.2% -72.0% -100.0% 0.0% 100.0% 146.1% -100.0% 0.0%
Cur. Ratio 3.03
1.68
2.19
1.40
1.43
1.35
1.37
1.03
2.27
1.16
1.13
growth rate -44.6% 30.4% -36.1% 2.1% -5.6% 1.5% -24.8% 120.4% -48.9% -2.6%
Quick Ratio 1.71
0.70
1.04
0.76
0.60
0.53
0.52
0.42
2.01
0.96
0.85
growth rate -59.1% 48.6% -26.9% -21.1% -11.7% -1.9% -19.2% 378.6% -52.2% -11.5%
Leverage 1.74
1.98
1.78
1.88
3.68
2.38
1.85
1.90
1.81
1.72
1.56
growth rate 13.8% -10.1% 5.6% 95.7% -35.3% -22.3% 2.7% -4.7% -5.0% -9.3%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 538.40
576.60
647.30
730.60
739.00
1,636.70
1,112.30
2,139.20
2,625.30
2,979.10
2,935.80
growth rate 7.1% 12.3% 12.9% 1.2% 121.5% -32.0% 92.3% 22.7% 13.5% -1.5%
Acct.Payable 871.10
1,041.40
2,474.90
323.30
215.90
224.90
324.50
349.80
growth rate 19.6% 137.7% -86.9% -33.2% 4.2% 44.3% 7.8%
Cur.Assets 2,270.60
3,106.30
3,993.70
4,048.30
4,934.90
4,434.70
7,110.60
8,579.10
17,857.90
11,376.70
6,475.40
growth rate 36.8% 28.6% 1.4% 21.9% -10.1% 60.3% 20.7% 108.2% -36.3% -43.1%
Total Assets 6,791.80
7,536.60
8,308.10
8,508.60
9,179.30
22,725.90
52,758.00
135,583.30
128,986.30
118,341.90
101,787.60
growth rate 11.0% 10.2% 2.4% 7.9% 147.6% 132.2% 157.0% -4.9% -8.3% -14.0%
Cash 1,110.40
1,947.10
1,991.20
2,406.10
2,701.80
329.00
250.00
1,096.00
1,724.00
1,817.20
880.40
growth rate 75.4% 2.3% 20.8% 12.3% -87.8% -24.0% 338.4% 57.3% 5.4% -51.6%
Inventory 262.50
213.90
229.40
249.70
272.30
1,786.30
984.60
757.50
718.00
904.50
846.90
growth rate -18.5% 7.3% 8.9% 9.1% 556.0% -44.9% -23.1% -5.2% 26.0% -6.4%
Cur.Liabilities 697.00
811.60
1,528.40
955.00
1,095.50
3,294.90
5,247.50
8,292.00
7,874.70
9,848.10
5,727.90
growth rate 16.4% 88.3% -37.5% 14.7% 200.8% 59.3% 58.0% -5.0% 25.1% -41.8%
Liabilities 2,741.10
2,713.80
3,550.40
3,199.00
3,342.20
13,193.80
24,422.50
58,994.00
52,785.80
44,504.80
36,656.60
growth rate -1.0% 30.8% -9.9% 4.5% 294.8% 85.1% 141.6% -10.5% -15.7% -17.6%
LT Debt 1,570.50
1,491.30
1,534.20
1,515.40
1,512.40
8,704.70
14,837.70
40,133.90
29,970.80
25,843.50
22,929.40
growth rate -5.0% 2.9% -1.2% -0.2% 475.6% 70.5% 170.5% -25.3% -13.8% -11.3%
Equity 4,050.70
4,822.80
4,757.70
5,309.60
5,837.10
9,532.10
28,331.10
71,661.70
71,263.00
68,891.40
65,114.10
growth rate 19.1% -1.4% 11.6% 9.9% 63.3% 197.2% 152.9% -0.6% -3.3% -5.5%
Common Shares 118.00
116.00
124.00
127.00
128.00
142.00
219.00
368.00
384.00
334.00
337.00
growth rate -1.7% 6.9% 2.4% 0.8% 10.9% 54.2% 68.0% 4.4% -13.0% 0.9%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 189.60
95.80
115.70
118.60
143.30
177.90
238.60
454.90
331.40
349.90
253.50
growth rate -49.5% 20.8% 2.5% 20.8% 24.2% 34.1% 90.7% -27.2% 5.6% -27.6%
Cash Dividends 60.70
60.60
60.60
61.10
60.40
59.40
208.10
208.10
278.40
1,218.20
1,049.80
growth rate -0.2% 0.0% 0.8% -1.2% -1.7% 250.3% 0.0% 33.8% 337.6% -13.8%
Cash From OA 682.50
1,113.30
463.90
1,081.90
1,599.90
1,213.50
2,243.00
4,606.10
1,445.70
6,079.00
5,640.10
growth rate 63.1% -58.3% 133.2% 47.9% -24.2% 84.8% 105.4% -68.6% 320.5% -7.2%
FCF per Share 2.68
2.62
4.05
4.18
4.04
4.65
8.76
9.67
6.71
8.22
17.05
growth rate -2.2% 54.6% 3.2% -3.4% 15.1% 88.4% 10.4% -30.6% 22.5% 107.4%
Sale Purchase of Stock -197.70
-662.60
-132.40
105.90
4,301.10
172.10
183.40
growth rate 0.0% 0.0% 100.0% 3,961.5% -96.0% 6.6%
FCF 316.00
304.00
504.00
487.00
519.00
906.00
1,968.00
3,920.00
1,092.00
4,909.00
5,387.00
growth rate -3.8% 65.8% -3.4% 6.6% 74.6% 117.2% 99.2% -72.1% 349.5% 9.7%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 4,403.40
4,503.60
4,919.40
5,216.00
5,646.60
2,602.50
4,676.50
12,688.10
14,570.60
15,940.70
15,787.40
growth rate 2.3% 9.2% 6.0% 8.3% -53.9% 79.7% 171.3% 14.8% 9.4% -1.0%
Op.Income 796.00
928.00
258.60
949.60
1,100.70
-467.50
-659.50
34.70
-365.20
65.20
384.50
growth rate 16.6% -72.1% 267.2% 15.9% -100.0% 0.0% 100.0% -100.0% 100.0% 489.7%
IBT 762.20
848.50
170.80
1,309.20
1,531.00
-622.80
-2,998.20
-4,547.50
-2,832.00
-10,386.40
-6,856.90
growth rate 11.3% -79.9% 666.5% 16.9% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Net Income 563.10
621.30
0.60
949.60
1,100.70
-467.50
-1,630.50
3,915.20
14,973.40
-4,125.50
-5,096.40
growth rate 10.3% -99.9% 158,166.7% 15.9% -100.0% 0.0% 100.0% 282.4% -100.0% 0.0%
EPS 2.09
1.96
1.48
2.06
0.76
-5.27
-7.42
10.01
38.18
-13.19
-15.26
growth rate -6.2% -24.5% 39.2% -63.1% -100.0% 0.0% 100.0% 281.4% -100.0% 0.0%
Gross Profit 3,642.20
3,752.70
4,197.40
4,498.00
4,895.40
957.80
3,693.00
11,218.90
12,765.90
13,795.30
13,521.40
growth rate 3.0% 11.9% 7.2% 8.8% -80.4% 285.6% 203.8% 13.8% 8.1% -2.0%
R&D 797.90
706.00
804.60
871.50
977.30
191.30
583.80
2,067.20
2,568.50
1,990.60
2,253.40
growth rate -11.5% 14.0% 8.3% 12.1% -80.4% 205.2% 254.1% 24.3% -22.5% 13.2%

Quarterly Statements

Item Name Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Earnings BIT 23.20
267.10
139.60
192.80
452.10
growth rate 1,051.3% -47.7% 38.1% 134.5%
Balance Sheet Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Acct.Receivable 2,760.80
2,826.90
2,935.80
2,731.20
3,086.30
growth rate 2.4% 3.9% -7.0% 13.0%
Acct.Payable 285.80
285.80
349.80
356.70
518.50
growth rate 0.0% 22.4% 2.0% 45.4%
Cur.Assets 6,103.70
5,740.20
6,475.40
6,289.30
8,605.30
growth rate -6.0% 12.8% -2.9% 36.8%
Total Assets 108,858.80
106,542.50
101,787.60
98,036.30
95,480.70
growth rate -2.1% -4.5% -3.7% -2.6%
Cash 1,674.70
1,187.90
880.40
788.50
1,651.40
growth rate -29.1% -25.9% -10.4% 109.4%
Inventory 922.50
894.60
846.90
943.20
1,004.50
growth rate -3.0% -5.3% 11.4% 6.5%
Cur.Liabilities 6,125.30
6,231.90
5,727.90
8,849.20
5,086.30
growth rate 1.7% -8.1% 54.5% -42.5%
Liabilities 37,594.80
36,021.60
36,656.60
36,476.70
35,784.60
growth rate -4.2% 1.8% -0.5% -1.9%
LT Debt 24,002.00
22,231.80
22,929.40
19,554.10
22,703.50
growth rate -7.4% 3.1% -14.7% 16.1%
Equity 71,243.50
70,507.80
65,114.10
61,542.00
59,696.10
growth rate -1.0% -7.7% -5.5% -3.0%
Common Shares 71,264.00
65,131.00
59,696.10
growth rate -4.4% -4.3%
Cash Flow Statement Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Capital Expenditures 60.10
58.60
88.40
64.80
87.50
growth rate -2.5% 50.9% -26.7% 35.0%
Cash Dividends 244.20
244.40
241.70
246.10
242.70
growth rate 0.1% -1.1% 1.8% -1.4%
Cash From OA 1,240.20
1,443.00
1,498.60
1,234.00
1,410.30
growth rate 16.4% 3.9% -17.7% 14.3%
Sale Purchase of Stock 33.70
growth rate
FCF 1,180.10
1,384.40
1,410.20
1,169.20
1,322.80
growth rate 17.3% 1.9% -17.1% 13.1%
Income Statement Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Sales 4,124.20
3,911.40
4,079.70
3,597.10
4,090.10
growth rate -5.2% 4.3% -11.8% 13.7%
Op.Income 23.20
267.10
139.60
192.80
452.10
growth rate 1,051.3% -47.7% 38.1% 134.5%
IBT -475.30
177.10
-5,592.60
-2,475.90
-1,453.30
growth rate 100.0% -100.0% 0.0% 0.0%
Net Income -472.50
-37.90
-4,299.90
-2,408.00
-1,759.00
growth rate 0.0% 0.0% 0.0% 0.0%
EPS
growth rate
Gross Profit 3,524.30
3,331.70
3,498.50
3,120.40
3,464.20
growth rate -5.5% 5.0% -10.8% 11.0%
R&D 667.00
443.80
674.20
432.00
447.20
growth rate -33.5% 51.9% -35.9% 3.5%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

D (38.53)

YOY Growth Grade:

E (29.37)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE 24.47 -10.44 8.38
EPS / Growth 15.0% -15.26 7.2%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 25.4%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 7.2% 15.9% 15.9%
Future PE 8.38 21.53 21.53
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.